Tralokinumab

Jun 12, 2020

Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life

Sep 06, 2019

Recent Studies Reveal Flare Rates Among Dupixent-Treated Patients with Moderate-to-Severe Atopic Dermatitis

Jan 15, 2019

Southeast Asia Atopic Dermatitis Therapeutics Markets to 2024 - How will Novel IL-4Ra Inhibitor Therapy Dupixent, which Holds First-to-Market Advantage, Contribute to Growth

Nov 07, 2018

Sanofi/Regeneron's Dupixent Continues to Flourish as the Only Atopic Dermatitis Game in Town, but US Dermatologists Identify a Gap Between Current Patients and Candidates for Treatment

May 03, 2018

Sanofi/Regeneron's Dupixent, the Darling of Atopic Dermatitis

Nov 14, 2017

FASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic Asthma

Oct 12, 2017

Global $41 Bn Respiratory Drugs Market to 2023 - Leading Players are GSK, AstraZeneca and Boehringer Ingelheim

Jun 15, 2017

LEO Pharma Starts Phase 3 Clinical Study for Tralokinumab in Atopic Dermatitis